Clinical Study
Combined Lung Transfer of NO and CO in Patients Receiving Methotrexate or Bleomycin Therapy Compared to Normal Subjects
Table 3
CO and NO lung transfers’ results in the three studied groups.
| | Group | MTX group | BLM group | |
| TLCO (%PV) | | | | 0.002 MTX versus N and 0.001 BLM versus N | TLNO (%PV) | | | | <0.0001 MTX versus N and <0.0001 BLM versus N | VA (%PV) | | | | NS | KCO (%PV) | | | | 0.02 BLM versus MTX, <0.0001 BLM versus N, and 0.05 MTX versus N | VI (%PV) | | | | 0.05 MTX versus N, 0.02 BLM versus MTX, and <0.0001 BLM versus N | TLCO/VI (VI%PV) | | | | 0.02 MTX versus N | Dm (%PV) | | | | <0.0001 MTX versus N and <0.0001 BLM versus N | Vc (%PV) | | | | <0.0001 MTX versus N and <0.0001 BLM versus N | TLNO/TLCO | | | | <0.0001 BLM versus N and 0.007 BLM versus MTX |
|
|
Values are given by mean ± standard error. is calculated by ANOVA. NS: not significant. %PV: percentage of predicted value.
|